This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Follitropin beta, Puregon (Europe)
Description: Follistim is a recombinant human follicle-stimulating hormone (FSH). FSH is normally produced in the anterior pituitary gland and stimulates growth of ovarian follicles, which contain the oocytes (eggs). Follistim is used to stimulate the development of multiple follicles in Assisted Reproductive Technology (ART) and induction of ovulation and pregnancy in anovulatory infertile patients.
Deal Structure: Serono receives royalty revenues from Organon onits sales of Puregon.
In November 2007, Schering-Plough completed the acquisition of Organon BioSciences N.V.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. Merck & Co and Schering-Plough announced that their merger completed on November 3, 2009.
Pink Sheet Organon Follistim male infertility approval
Pink Sheet Follistim-AQ “not approvable”
Additional information available to subscribers only: